Managing current drug shortages
At any given time, there are between 1500 and 2000 active drug shortages in Canada. In many of these cases, pharmacists play an important and effective role in managing shortages at the pharmacy level. Below you will find information and resources related to several current shortages that may have a widespread impact on patients and pharmacies.
- Acetaminophen with oxycodone or codeine
- Menopausal Hormone Therapy
- Zaroxolyn (Metolazone)
- Proton Pump Inhibitors (PPIs)
- Captopril
- Hydromorphone immediate-release tablets
- Cyclophosphamide
- Oseltamivir (Tamiflu) suspension potential supply constraints
- Ipratropium solution for nebules
- Lomustine discontinuation
- Peginterferon alfa-2a (Pegasys)
- Hypurin (porcine insulin) discontinuation
- Lithium carbonate
Our role: CPhA works closely with Health Canada and others to represent the pharmacy profession. This includes advocating on pharmacists’ behalf, communicating shortage updates and recommendations, collecting frontline data to help inform allocation and procurement strategies, and developing tools and resources to support pharmacy and patients.
Acetaminophen with oxycodone or codeine
Supply challenges have been reported for certain acetaminophen with oxycodone and acetaminophen with codeine products in Canada, including:
- Teva-Oxycocet
- Teva-Lenoltec No. 3, and No. 4
Supply of Teva-Oxycocet remains limited, with additional shipments expected in November and December and further resupply anticipated in early 2027. Supply constraints may be particularly challenging in December. Additional shipments of Teva-Lenoltec No. 3 are expected in November, while resupply of Teva-Lenoltec No. 4 is anticipated in early December.
Health Canada is working with manufacturers and is closely monitoring the supply situation.
Information and resources
To support pharmacists, CPhA developed a clinical resource with guidance on patient management and therapeutic alternatives:
Menopausal Hormone Therapy
Supply challenges continue to affect some estrogen products in Canada, including estradiol transdermal patches. Intermittent shortages are expected to persist until early 2027, meaning patients may find that certain strengths are temporarily unavailable at their pharmacy. The shortages are linked to global supply challenges, including increased demand and manufacturing disruptions.
In addition, Pfizer has announced that it is discontinuing its Premarin products in Canada. Premarin vaginal cream is already out of stock, while Premarin tablets (all strengths) and injectable formulations will be discontinued by June 2027.
Health Canada is working with manufacturers and stakeholders to monitor supply and mitigate the impact of the shortages. Alternative products are currently available, although coverage may vary. See Health Canada’s supply notice for more information.
Information and resources
CPhA has developed a clinical resource to support pharmacists as they help patients navigate this shortage and available alternatives.
- Menopausal Hormone Therapy Shortage (CPhA)
- Menopause Hormone Therapy – Estradiol Transdermal Patches in short supply in Canada: Notice (Health Canada)
Zaroxolyn (Metolazone)
Supply disruptions are affecting Zaroxolyn (metolazone), with shortages expected to continue until December 2026. The shortage is related to delays in resupply.
To help conserve available supply and minimize treatment interruptions, pharmacists are encouraged to consider the following measures:
- Limit dispensing to a 30-day supply, where appropriate.
- Monitor available inventory and anticipate potential supply disruptions.
- Work with patients and prescribers to identify appropriate treatment options if supply is unavailable.
Proton Pump Inhibitors (PPIs)
Supply challenges are affecting several proton pump inhibitors (PPIs) in Canada, including pantoprazole magnesium, rabeprazole and lansoprazole. Shortages of pantoprazole magnesium are expected to continue until January 2027. At this time, no supply issues have been reported for omeprazole or pantoprazole sodium.
To help manage available supply and minimize disruptions to patient care, pharmacists are encouraged to consider the following measures:
- Limit dispensing of affected PPIs to a 30-day supply, where appropriate.
- Consider alternative treatment options before initiating new patients on affected PPIs.
- Review opportunities for deprescribing or adjusting therapy where clinically appropriate. For guidance, consult:
- CPS chapter: Deprescribing
- Deprescribing Guidelines and Algorithms (deprescribing.org)
- Work with patients and prescribers to identify suitable alternatives, taking into account individual treatment needs, previous treatment experience and patient preferences.
Etanercept
Sandoz Canada has reported a shortage of etanercept for injection, 25 mg/0.5 mL, due to a manufacturing disruption. The shortage is expected to continue until February 12, 2027. Sandoz is the sole supplier of this strength in Canada.
Health Canada designated the shortage as Tier 3 on November 12, 2026, recognizing its potential impact on patient care.
The use of 50 mg/mL etanercept is not a recommended substitute for 25 mg dosing, as 25 mg doses cannot be reliably/safely obtained from a 50 mg/mL single-use prefilled syringe/autoinjector.
Alternative mitigation would be to switch patients to Adalimumab, where clinically appropriate. However, this would require additional monitoring.
Captopril
Supply of captopril tablets is limited following the discontinuation of Teva's products and ongoing manufacturing disruptions affecting several Apotex strengths. While oral solution formulations remain available, tablet supplies are expected to become increasingly constrained over time.
This shortage does not currently meet the criteria for a Tier 3 shortage. The supply situation will continue to be monitored, and additional conservation measures may be considered if availability worsens.
Information and Resources
A clinical resource has been developed to support health-care professionals during the shortage, outlining therapeutic alternatives, ACE inhibitor conversion guidance and practice considerations to assist with patient management and inventory stewardship.
- Captopril Shortage (CPhA, Canadian Society of Healthcare Systems Pharmacy, Canadian Cardiovascular Society, Canadian Neurological Sciences Federation and Canadian Paediatric Society)
Hydromorphone immediate-release tablets
Canada is experiencing supply constraints affecting hydromorphone immediate-release (IR) 1 mg and 2 mg tablets. The supply constraints are related to manufacturing and supply challenges affecting multiple manufacturers of these strengths.
Current information suggests that supply constraints may continue through August and September and could persist beyond initially anticipated resolution timelines. While supply of 4 mg and 8 mg hydromorphone IR tablets remains stable, demand for the lower-strength tablets is significantly higher, and these products may not fully offset the expected supply gap.
Health Canada is monitoring the situation and continues to work with manufacturers and stakeholders to assess product availability.
Information and resources
To support pharmacists during these anticipated supply constraints, CPhA, in collaboration with the Canadian Society of Healthcare-Systems Pharmacy (CSHP), has developed a clinical resource with recommendations for patient management, conservation strategies and therapeutic alternatives.
Cyclophosphamide
There is an ongoing shortage of cyclophosphamide for injection in Canada. All three manufacturers supplying the Canadian market—Baxter, Sterimax and Andone Pharmaceuticals—are reporting shortages across multiple vial sizes, and the shortage is expected to continue into the spring. On February 20, 2026, Health Canada declared a Tier 3 drug shortage and is working with manufacturers and stakeholders to monitor and mitigate the situation, including the importation of foreign-authorized products.
Information and resources
CPhA, the Canadian Society of Healthcare-Systems Pharmacy (CSHP) and the Canadian Association of Pharmacy in Oncology (CAPhO), have developed a clinical resource to support pharmacists and other health-care professionals in managing this shortage.
- Cyclophosphamide Shortage (CPhA/CSHP/CAPhO)
Oseltamivir (Tamiflu) suspension
With the increase in cases of influenza, demand for oseltamivir (Tamiflu) suspension formula has increased. In anticipation of potential supply constraints in the coming weeks, efforts should be made to conserve suspension supply where possible.
Oseltamivir capsules remain in good supply and there is no indication of a broad or system-wide shortage. While we expect children’s hospitals to be the most affected, community pharmacists may also encounter this issue, particularly those not located near a tertiary children’s hospital. There may also be impacts for pharmacies serving long-term care or other populations with swallowing difficulties.
Vaccination remains the most effective method for preventing influenza and its complications during respiratory virus season.
Information and resources
CSHP and CPhA have developed a clinical resource to support health professionals in managing patients prescribed oseltamivir during any potential supply constraints for the suspension formulation:
Ipratropium solution for nebules
Health Canada has declared a Tier 3 shortage of ipratropium nebules. Both Teva and Pharmascience are reporting shortages due to manufacturing disruptions and supply is constrained across the country. Intermittent shortages and supply gaps are projected to last into 2026.
Health Canada is monitoring the situation closely and assessing the supply of related products.
Information and resources
CPhA and medSask have developed a clinical resource to support health professionals in managing patients prescribed ipratropium bromide during the shortage.
- Ipratropium Bromide Shortage (CPhA/medSask)
Spironolactone
Health Canada has declared a Tier 3 shortage of spironolactone tablets.
Spironolactone is marketed by Teva Canada Ltd, Jamp Pharma Corporation, Mint Pharmaceuticals and Pfizer Canada ULC in 25 mg and 100 mg strengths.
Teva Canada Ltd and Mint Pharmaceuticals are reporting shortages because of manufacturing disruptions, and Pfizer Canada ULC is reporting a shortage because of increased demand. As a result, Spironolactone may not always be available.
Additional resupplies are anticipated in October and November; however, ongoing demand and substitution between strengths may continue to strain availability. Health Canada is working with manufacturers and others to monitor and mitigate the shortage. See Health Canada’s supply notice for more information.
Information and resources
A clinical resource has been developed to support health professionals in managing patients prescribed spironolactone during the shortage.
- Spironolactone Shortage (CPhA, CSHP, CCS, CHFS)
- Notice: Spironolactone in short supply (Health Canada)
Lomustine discontinuation
In Canada, Lomustine is marketed by Bristol Myers Squibb (BMS) under the brand name CeeNU in 10 mg and 40 mg capsules. BMS has announced it will be discontinuing the drug in Canada. To help mitigate the impact of this discontinuation, Health Canada worked with BMS to extend the allowable shelf-life for the current inventory of CeeNU. Health Canada is also working with manufacturers and stakeholders to identify strategies to ensure access to Lomustine for Canadian patients following discontinuation of CeeNU (Lomustine), including importation. See Health Canada’s supply notice for more information.
Information and resources
- CeeNU (Lomustine) supply in Canada: Notice (Health Canada)
- Expiry Date Extension of CeeNU (lomustine) lots (Bristol Myers Squibb)
Peginterferon alfa-2a (Pegasys)
There continues to be a shortage of Canadian-authorized Pegasys (peginterferon alfa-2a) injection in Canada. Given the serious risks this shortage presents to patients in Canada who have been prescribed interferon-based therapy for treating myeloproliferative neoplasms (MPNs), Health Canada has permitted the exceptional, temporary importation and sale of similar but not identical products:
- Health Canada has authorized the exceptional importation of EU-authorized PEGASYS (peginterferon alfa-2a). Available supplies are expected to be adequate to meet full market demand.
- Health Canada had previously authorized the exceptional importation of US-authorized BESREMi (ropeginterferon alfa-2b). Supplies are expected to remain available to allow patients already initiated on the drug to continue treatment.
Canadian-authorized PEGASYS is not expected to be available until the end of June 2026.To support your patients during this shortage:
- Do not initiate new patients on Pegasys.
- Do not order or dispense large quantities of Pegasys.
- For patients MPNs, consider alternative medication as per guidance from the Canadian MPN Network: Guidance on transition is available here.
- Cutaneous T-cell lymphoma (CTCL) patients and pregnant patients should not be switched to Besremi. Pegasys remains the preferred interferon in this population as per guidance from the Canadian MPN Network.
- If a patient cannot be switched to Besremi, it is crucial to optimize dosing by using the lowest effective dose as per the Canadian MPN network.
- Please note that there are differences in the Besremi and Pegasys syringe format. Besremi is only available in a single dose pre-filled syringe with a manual safety needle cap. Counselling patients when converting patients will be required.
Further information about the shortage and guidance for health-care professionals can be found below.
Information and resources
- PEGASYS (peginterferon alfa-2A) injection in short supply: Notice (Health Canada)
- Health professional risk communication: Importation of US-Authorized BESREMi (Ropeginterferon alfa-2b-njft) Injection Due to the Current Shortage of Canadian-Authorized PEGASYS (Peginterferon alfa-2a) Injection (Health Canada)
- Clinical Guidance on the Use of Ropeginterferon alfa-2b (Ropeg) and Peginterferon alfa-2a (Pegasys) in MPNs and CTCL (Canadian MPN Group)
Hypurin (porcine insulin) discontinuation
Wockhardt UK, the only current, global supplier of porcine insulin has informed Health Canada that it will no longer supply porcine insulin products for the Canadian market. Health Canada is working with the importer to monitor the remaining supply and is exploring ways to extend the availability of animal-sourced insulin by importing a UK-authorized supply that expires May 2026. No additional inventory of these drugs will be available after this inventory has been depleted. See Health Canada’s supply notice for more information.
Information and resources
CPhA, the Canadian Society of Healthcare-Systems Pharmacy (CSHP) and the Canadian Society of Endocrinology and Metabolism (CESM) have developed the following resource to help support pharmacists and other health-care providers manage the discontinuation.
- Hypurin (porcine insulin) discontinuation (CPhA, CSHP, CESM)
- Notice: Animal-sourced insulin discontinuation (Health Canada)
Lithium carbonate
Canada has been experiencing shortages of lithium carbonate since summer 2024, predominantly impacting 300mg oral lithium products. A tier 3 shortage was declared on July 25, 2024. Health Canada continues to closely monitor the supply situation.
Information and resources
CPhA has developed the following clinical resource to support pharmacists as they help their patients navigate this shortage and available alternatives.
- Lithium Shortage (CPhA)
